Abstract:Pharmacokinetic-pharmacodynamic (PKPD) modeling and simulation has evolved as an important tool for rational drug development and drug use, where developed models characterize both the typical trends in the data and quantify the variability in relationships between dose, concentration, and desired effects and side effects. In parallel, rapid emergence of antibiotic-resistant bacteria imposes new challenges on modern health care. Models that can characterize bacterial growth, bacterial killing by antibiotics and immune system, and selection of resistance can provide valuable information on the interactions between antibiotics, bacteria, and host. Simulations from developed models allow for outcome predictions of untested scenarios, improved study designs, and optimized dosing regimens. Today, much quantitative information on antibiotic PKPD is thrown away by summarizing data into variables with limited possibilities for extrapolation to different dosing regimens and study populations. In vitro studies allow for flexible study designs and valuable information on time courses of antibiotic drug action. Such experiments have formed the basis for development of a variety of PKPD models that primarily differ in how antibiotic drug exposure induces amplification of resistant bacteria. The models have shown promise for efficacy predictions in patients, but few PKPD models describe time courses of antibiotic drug effects in animals and patients. We promote more extensive use of modeling and simulation to speed up development of new antibiotics and promising antibiotic drug combinations. This review summarizes the value of PKPD modeling and provides an overview of the characteristics of available PKPD models of antibiotics based on in vitro, animal, and patient data.

In vitro pharmacokinetic models and their applications in antibiotics research

Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs

Progress on pharmacokinetics/pharmacodynamics of antimicrobial agents

Prediction of Metabolic Drug Interaction in vivo by Using in vitro Drug Metabolism Data

Short-term ex vivo tissue culture models help study human lung infectionsA review

Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction

The Application of Population Pharmacokinetic Model to Individualized Antibiotic Therapy

Introduction of mechanism-based pharmacokinetic/pharmacodynamic models

Animal pharmacokinetics/pharmacodynamics (PK/PD) infection models for clinical development of antibacterial drugs: lessons from selected cases.

Complex in Vitro Model: A Transformative Model in Drug Development and Precision Medicine

Crossing the Chasm: How to Approach Translational Pharmacokinetic-Pharmacodynamic Modeling of Phage Dosing

Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves

Revitalizing antibiotic discovery and development through in vitro modelling of in-patient conditions

Predicting the dynamics of bacterial growth inhibition by ribosome-targeting antibiotics

Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development

Development of a Population Pharmacokinetic Model of Vancomycin and Its Application in Chinese Geriatric Patients with Pulmonary Infections

Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs

The Spread of Antibiotic Resistance Genes In Vivo Model

Interest in antibiotic pharmacokinetic modelling in the context of optimising dosing and reducing resistance: bibliometric analysis

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models